• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与皮下注射替诺福韦相比，口服替诺福韦富马酸酯在感染猴免疫缺陷病毒的猕猴体内将药物优先集中到肠道相关淋巴样细胞中。

Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.

机构信息

California National Primate Research Center, University of California, Davis, California, USA.

出版信息

Antimicrob Agents Chemother. 2012 Sep;56(9):4980-4. doi: 10.1128/AAC.01095-12. Epub 2012 Jul 9.

DOI:10.1128/AAC.01095-12
PMID:22777046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3421865/
Abstract

To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate (TDF) versus subcutaneous tenofovir (TFV), macaques were treated for 2 weeks starting 1 week after simian immunodeficiency virus inoculation. Despite lower plasma TFV levels in the oral TDF arm, similar TFV diphosphate levels and antiviral activities were measured in lymphoid cells of most tissues. In intestinal tissues, however, oral TDF resulted in higher active drug levels, associated with lower virus levels and better immune preservation.

摘要

为了比较口服替诺福韦二吡呋酯（TDF）与替诺福韦（TFV）的组织药代动力学和疗效，猕猴在感染猴免疫缺陷病毒 1 周后开始接受为期 2 周的治疗。尽管口服 TDF 组的血浆 TFV 水平较低，但在大多数组织的淋巴细胞中测量到相似的 TFV 二磷酸酯水平和抗病毒活性。然而，在肠道组织中，口服 TDF 导致更高的活性药物水平，与更低的病毒水平和更好的免疫保护相关。

相似文献

1
Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.与皮下注射替诺福韦相比，口服替诺福韦富马酸酯在感染猴免疫缺陷病毒的猕猴体内将药物优先集中到肠道相关淋巴样细胞中。
Antimicrob Agents Chemother. 2012 Sep;56(9):4980-4. doi: 10.1128/AAC.01095-12. Epub 2012 Jul 9.
2
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.从婴儿期到成年期及孕期恒河猴长期服用替诺福韦：药代动力学、生物学及病毒学效应总结
Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23.
3
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.天然底物浓度可以调节核苷酸 HIV 逆转录酶抑制剂的预防效果。
J Virol. 2011 Jul;85(13):6610-7. doi: 10.1128/JVI.00311-11. Epub 2011 Apr 27.
4
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.替诺福韦凝胶对猕猴阴道内感染猴免疫缺陷病毒的持久保护作用及其与组织中药物水平的关系。
J Virol. 2012 Jan;86(2):718-25. doi: 10.1128/JVI.05842-11. Epub 2011 Nov 9.
5
Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.核苷酸类似物前药替诺福韦酯在猴子口服给药后可增强淋巴细胞摄取。
Mol Pharm. 2009 Jul-Aug;6(4):1145-51. doi: 10.1021/mp900036s.
6
Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.口服恩曲他滨和替诺福韦酯联合治疗预防含有 K65R 突变的耐替诺福韦的猴/人免疫缺陷病毒在猕猴中的疗效。
J Infect Dis. 2013 Aug 1;208(3):463-7. doi: 10.1093/infdis/jit189. Epub 2013 Apr 30.
7
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.评估口服富马酸替诺福韦二吡呋酯和外用替诺福韦GS-7340对保护幼龄猕猴免受毒性猿猴免疫缺陷病毒反复口服攻击的作用。
J Acquir Immune Defic Syndr. 2006 Sep;43(1):6-14. doi: 10.1097/01.qai.0000224972.60339.7c.
8
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.短暂的接种后早期抗逆转录病毒治疗有助于在感染SIVmac239的恒河猴肠道相关淋巴组织中实现可控感染并保留CD4+ T细胞，但不能抵抗再次感染。
J Med Primatol. 2003 Aug;32(4-5):201-10. doi: 10.1034/j.1600-0684.2003.00026.x.
9
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.替诺福韦经阴道和直肠给猴施用后替诺福韦的药代动力学。
Antimicrob Agents Chemother. 2012 Jan;56(1):103-9. doi: 10.1128/AAC.00597-11. Epub 2011 Oct 10.
10
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.对口服接种对9-[2-(R)-(膦酰甲氧基)丙基]腺嘌呤（PMPA）敏感性降低的猿猴免疫缺陷病毒的新生猕猴进行短期9-[2-(R)-(膦酰甲氧基)丙基]腺嘌呤（PMPA）给药的预防和治疗益处。
J Virol. 2000 Feb;74(4):1767-74. doi: 10.1128/jvi.74.4.1767-1774.2000.

引用本文的文献

1
SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity.早期开始治疗的猕猴中猴免疫缺陷病毒缓解及超长效抗病毒活性
Nat Commun. 2024 Dec 4;15(1):10550. doi: 10.1038/s41467-024-54783-0.
2
Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques.病毒传播和免疫激活调节 SIV 感染恒河猴淋巴结中的抗逆转录病毒药物水平。
Front Immunol. 2023 Sep 18;14:1213455. doi: 10.3389/fimmu.2023.1213455. eCollection 2023.
3
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.三种 HIV 药物联合用药的生理基于药代动力学模型及皮下给药后淋巴系统的作用。第 1 部分：游离药物混合物模型。
J Pharm Sci. 2022 Feb;111(2):529-541. doi: 10.1016/j.xphs.2021.10.007. Epub 2021 Oct 19.
4
A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.一种新型组合双替加韦/替诺福韦艾拉酚胺纳米制剂用于 HIV-1 暴露前预防的概念评估研究
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02320-20.
5
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.富马酸替诺福韦二吡呋酯和替诺福韦艾拉酚胺在感染 HIV 人群中的淋巴组织药代动力学。
Clin Pharmacol Ther. 2020 Nov;108(5):971-975. doi: 10.1002/cpt.1883. Epub 2020 Jun 11.
6
Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies.训练恒河猴每日口服抗逆转录病毒疗法，用于 HIV 预防和治疗策略的临床前评估。
PLoS One. 2019 Nov 15;14(11):e0225146. doi: 10.1371/journal.pone.0225146. eCollection 2019.
7
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.基于机制的药代动力学（MBPK）模型描述了一种长效抗 HIV 药物组合纳米颗粒制剂递送的三种抗逆转录病毒药物在血浆中的复杂动力学。
J Control Release. 2018 Apr 10;275:229-241. doi: 10.1016/j.jconrel.2018.02.003. Epub 2018 Feb 10.
8
Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice.替诺福韦酯富马酸盐：小鼠口服给药13周后的毒性、毒代动力学及毒理基因组学分析
Int J Toxicol. 2015 Jan-Feb;34(1):4-10. doi: 10.1177/1091581814565669. Epub 2015 Jan 7.
9
Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.在一个以存在主要血浆克隆和缺乏病毒进化为特征的RT-SHIV恒河猴高效抗逆转录病毒治疗（HAART）模型中的残余病毒血症。
PLoS One. 2014 Feb 5;9(2):e88258. doi: 10.1371/journal.pone.0088258. eCollection 2014.

本文引用的文献

1
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.在原发性感染期间开始联合抗病毒治疗的患者的肠道相关淋巴组织中未发现 HIV-1 进化。
PLoS Pathog. 2012 Feb;8(2):e1002506. doi: 10.1371/journal.ppat.1002506. Epub 2012 Feb 2.
2
HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts.艾滋病研究。组织称血液具有误导性，使艾滋病治愈工作陷入混乱。
Science. 2011 Dec 23;334(6063):1614. doi: 10.1126/science.334.6063.1614.
3
Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.HIV-1 感染患者中替诺福韦的血浆和细胞内群体药代动力学分析。
Antimicrob Agents Chemother. 2011 Nov;55(11):5294-9. doi: 10.1128/AAC.05317-11. Epub 2011 Sep 6.
4
The emerging race to cure HIV infections.治愈艾滋病毒感染的新竞赛。
Science. 2011 May 13;332(6031):784-5, 787-9. doi: 10.1126/science.332.6031.784.
5
Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.针对婴儿恒河猴口服 SIV 挑战的 VSV-SIV/MVA-SIV 疫苗方案的部分疗效。
Vaccine. 2011 Apr 12;29(17):3124-37. doi: 10.1016/j.vaccine.2011.02.051. Epub 2011 Mar 4.
6
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.在感染 HIV-1 的患者中同时给予替诺福韦酯和地达诺新时细胞内核苷酸水平。
Antimicrob Agents Chemother. 2011 Apr;55(4):1549-55. doi: 10.1128/AAC.00910-10. Epub 2011 Jan 31.
7
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.男男性行为人群 HIV 预防的暴露前药物预防。
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
8
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.口服替诺福韦间歇性预防可保护猕猴免受直肠 SHIV 感染。
Sci Transl Med. 2010 Jan 13;2(14):14ra4. doi: 10.1126/scitranslmed.3000391.
9
Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.核苷酸类似物前药替诺福韦酯在猴子口服给药后可增强淋巴细胞摄取。
Mol Pharm. 2009 Jul-Aug;6(4):1145-51. doi: 10.1021/mp900036s.
10
HIV infection and the gastrointestinal immune system.HIV感染与胃肠道免疫系统。
Mucosal Immunol. 2008 Jan;1(1):23-30. doi: 10.1038/mi.2007.1.